9 Participants Needed

Fetal Cystoscopy for Severe Lower Urinary Tract Obstruction

RR
Overseen ByRodrigo Ruano, MD, Ph.D
Age: 18+
Sex: Female
Trial Phase: Academic
Sponsor: Rodrigo Ruano
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 2 JurisdictionsThis treatment is already approved in other countries

Trial Summary

What is the purpose of this trial?

This trial studies the outcomes of medical procedures on unborn babies to treat serious urinary blockages. It focuses on pregnant women and their fetuses with severe urinary tract obstructions. The treatment aims to clear the blockage, allowing normal urine flow and aiding in fetal development.

Do I need to stop my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What data supports the effectiveness of the treatment Fetal Cystoscopy for Severe Lower Urinary Tract Obstruction?

Research shows that fetal cystoscopy can help diagnose and treat lower urinary tract obstructions in unborn babies. It has been successfully used to identify and treat conditions like posterior urethral valves, improving the ability to manage these issues before birth.12345

Is fetal cystoscopy generally safe for humans?

Fetal cystoscopy has been performed successfully in some cases to treat lower urinary tract obstructions in fetuses, but more studies are needed to fully understand its risks and limitations. It is considered less invasive than open fetal surgery, which may reduce the risk of preterm labor.12456

How is the treatment Fetal Cystoscopy different from other treatments for severe lower urinary tract obstruction?

Fetal Cystoscopy is unique because it allows doctors to directly view and treat the fetus's urinary tract while still in the womb, which can help diagnose and address blockages more accurately than traditional ultrasound. This approach can also enable specific interventions, like removing obstructions, that are not possible with other treatments like vesicoamniotic shunting.12345

Research Team

RR

Rodrigo Ruano, MD, Ph.D

Principal Investigator

University of Miami

Eligibility Criteria

This trial is for pregnant women over 18 with a male fetus diagnosed with severe LUTO, between 16 and nearly 26 weeks gestation. The fetus must have no chromosomal abnormalities or unrelated anomalies, and the mother should have favorable urine analysis results without prior in utero interventions. Women must not be at increased risk of preterm labor or have conditions that complicate surgery.

Inclusion Criteria

My male fetus has a blocked urinary tract, swollen bladder, keyhole sign, and kidney swelling.
Gestational age at the time of the procedure will be between 16 0/7 weeks and 25 6/7 weeks
My recent urine tests show low levels of sodium, chloride, and osmolality without any prior fetal treatments.
See 7 more

Exclusion Criteria

I am carrying a female fetus.
I cannot have surgery due to a previous cut in my uterus.
I choose not to undergo invasive tests.
See 12 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Fetal Cystoscopy Procedure

Participants undergo fetal cystoscopy procedure between 16 weeks 0 days to 25 weeks and 6 days of gestation

1 day
1 visit (in-person)

Post-Procedure Monitoring

Participants are monitored for immediate outcomes and complications post-procedure

1 day

Follow-up

Participants are monitored for safety and effectiveness after delivery, including prevention of severe pulmonary hypoplasia and renal impairment

Up to 24 months post delivery

Treatment Details

Interventions

  • Fetal Cystoscopy
Trial Overview The study tests fetal cystoscopy outcomes on mothers and fetuses facing severe isolated LUTO at University of Miami/Jackson Health System. It involves using tiny instruments to view and potentially treat urinary blockages in the fetus during pregnancy.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Fetal Cystoscopy GroupExperimental Treatment2 Interventions
Participants in this group will receive the fetal cystoscopy procedure around 16 weeks 0 days to 25 weeks and 6 days of gestation.

Fetal Cystoscopy is already approved in European Union, United States for the following indications:

๐Ÿ‡ช๐Ÿ‡บ
Approved in European Union as Fetal Cystoscopy for:
  • Severe Lower Urinary Tract Obstruction (LUTO)
๐Ÿ‡บ๐Ÿ‡ธ
Approved in United States as Fetal Cystoscopy for:
  • Severe Lower Urinary Tract Obstruction (LUTO)

Find a Clinic Near You

Who Is Running the Clinical Trial?

Rodrigo Ruano

Lead Sponsor

Trials
5
Recruited
40+

Findings from Research

Fetal cystoscopy can change the ultrasound diagnosis of congenital lower urinary tract obstruction in a significant percentage of cases, with alterations noted in 36.4% and 25.0% of fetuses in two studies.
While fetal cystoscopy showed a high odds ratio for improved perinatal survival compared to no treatment (20.51), it did not demonstrate a significant advantage over vesicoamniotic shunt, indicating that its effectiveness as a therapeutic intervention remains uncertain and requires further research.
Effectiveness of fetal cystoscopy as a diagnostic and therapeutic intervention for lower urinary tract obstruction: a systematic review.Morris, RK., Ruano, R., Kilby, MD.[2022]
A successful case of percutaneous fetal cystoscopy was performed on a male fetus at 19 weeks of gestation, confirming the diagnosis of posterior urethral valves and allowing for therapeutic intervention at 22 weeks.
This case demonstrates the potential of fetal cystoscopy as a feasible method for diagnosing and treating congenital urinary tract anomalies, although further studies are necessary to evaluate its overall effectiveness and safety.
Percutaneous fetal cystoscopy and endoscopic fulguration of posterior urethral valves.Quintero, RA., Hume, R., Smith, C., et al.[2019]
Fetal cystoscopy accurately diagnosed the cause of lower urinary tract obstruction (LUTO) in 91.4% of cases, allowing for targeted prenatal treatment.
Among fetuses diagnosed with posterior urethral valves (PUV), 56.7% survived to infancy, with 76.5% of those having normal renal function at 1 year, indicating that fetal cystoscopy can lead to improved outcomes for certain conditions.
Two-year outcomes after diagnostic and therapeutic fetal cystoscopy for lower urinary tract obstruction.Sananes, N., Cruz-Martinez, R., Favre, R., et al.[2017]

References

Effectiveness of fetal cystoscopy as a diagnostic and therapeutic intervention for lower urinary tract obstruction: a systematic review. [2022]
Percutaneous fetal cystoscopy and endoscopic fulguration of posterior urethral valves. [2019]
Two-year outcomes after diagnostic and therapeutic fetal cystoscopy for lower urinary tract obstruction. [2017]
Fetal intervention for severe lower urinary tract obstruction: a multicenter case-control study comparing fetal cystoscopy with vesicoamniotic shunting. [2016]
In-utero percutaneous cystoscopy in the management of fetal lower obstructive uropathy. [2019]
Fetoscopic surgery for the treatment of congenital anomalies. [2019]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of ServiceยทPrivacy PolicyยทCookiesยทSecurity